Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Type I interferons have long been appreciated as a cytokine family that regulates antiviral immunity. Recently, their role in eliciting antitumor immune responses has gained increasing attention. Within the immunosuppressive tumor microenvironment (TME), interferons stimulate tumor-infiltrating lymphocytes to promote immune clearance and essentially reshape a "cold" TME into an immune-activating "hot" TME. In this review, we focus on gliomas, with an emphasis on malignant glioblastoma, as these brain tumors possess a highly invasive and heterogenous brain TME. We address how type I interferons regulate antitumor immune responses against malignant gliomas and reshape the overall immune landscape of the brain TME. Furthermore, we discuss how these findings can translate into future immunotherapies targeting brain tumors in general.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247981PMC
http://dx.doi.org/10.3389/fimmu.2023.1203929DOI Listing

Publication Analysis

Top Keywords

brain tumors
12
type interferons
8
antitumor immune
8
immune responses
8
brain tme
8
brain
5
tme
5
harnessing type
4
type interferon-mediated
4
interferon-mediated immunity
4

Similar Publications

Central nervous system (CNS) diseases, including neurodegenerative diseases, stroke, brain tumors, and others, result in poor quality of life and can cause substantial disability. Not all CNS diseases are amenable to surgical approaches, so drug development is important for disease treatment. Unfortunately, there are few drugs currently available for CNS diseases.

View Article and Find Full Text PDF

Utility and performance of cerebrospinal fluid cytology in discriminating central nervous system infections and brain tumors.

J Neurooncol

September 2025

Department of Neurology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan Province, China.

Background And Objective: Differentiating central nervous system infections (CNSIs) from brain tumors (BTs) is difficult due to overlapping features and the limited individual indicators, and cerebrospinal fluid (CSF) cytology remains underutilized. To improve differential diagnosis, we developed a model based on 9 early, cost-effective cerebrospinal fluid parameters, including CSF cytology.

Methods: Patients diagnosed with CNSIs or BTs at Xiangya Hospital of Central South University between October 1st, 2017 and March 31st, 2024 were enrolled and divided into the training set and the test set.

View Article and Find Full Text PDF

Causes of Death After Surgery Among Cancer Patients: A Population-based Cohort Study.

Int J Surg

September 2025

State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Introduction: Recent advancements in surgical techniques and perioperative care have improved cancer survival rates, yet postoperative comorbidity and mortality remain a critical concern. Despite progress in cancer control, systematic analyses of long-term mortality trends and competing risks in surgery-intervened cancer populations are lacking. This study aimed to quantify temporal patterns of postoperative mortality causes across 21 solid cancers and identify dominant non-cancer risk factors to inform survivorship care strategies.

View Article and Find Full Text PDF

Aim    Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods    The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine.

View Article and Find Full Text PDF